

Overactive Bladder Drug-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/O3E6C6A7089MEN.html>

Date: March 2018

Pages: 148

Price: US\$ 3,480.00 (Single User License)

ID: O3E6C6A7089MEN

Abstracts

Report Summary

Overactive Bladder Drug-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Overactive Bladder Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Overactive Bladder Drug 2013-2017, and development forecast 2018-2023

Main market players of Overactive Bladder Drug in United States, with company and product introduction, position in the Overactive Bladder Drug market

Market status and development trend of Overactive Bladder Drug by types and applications

Cost and profit status of Overactive Bladder Drug, and marketing status

Market growth drivers and challenges

The report segments the United States Overactive Bladder Drug market as:

United States Overactive Bladder Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Overactive Bladder Drug Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Others

United States Overactive Bladder Drug Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

United States Overactive Bladder Drug Market: Players Segment Analysis (Company and Product introduction, Overactive Bladder Drug Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma, Inc. (Japan)

Pfizer, Inc. (U.S.)

Teva Pharmaceutical Industries Limited (Israel)

Allergan, Plc (Ireland)

Medtronic plc (Ireland)

Mylan N.V. (U.S.)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Sanofi (France)

Apotex, Inc. (Canada)

Cogentix Medical, Inc. (U.S.)

Aurobindo Pharma Limited (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OVERACTIVE BLADDER DRUG

- 1.1 Definition of Overactive Bladder Drug in This Report
- 1.2 Commercial Types of Overactive Bladder Drug
 - 1.2.1 Anticholinergics
 - 1.2.2 Solifenacin
 - 1.2.3 Oxybutynin
 - 1.2.4 Darifenacin
 - 1.2.5 Fesoterodine
 - 1.2.6 Tolterodine
 - 1.2.7 Trospium
 - 1.2.8 Others
- 1.3 Downstream Application of Overactive Bladder Drug
 - 1.3.1 Idiopathic Bladder Overactivity
 - 1.3.2 Neurogenic Bladder Overactivity
- 1.4 Development History of Overactive Bladder Drug
- 1.5 Market Status and Trend of Overactive Bladder Drug 2013-2023
 - 1.5.1 United States Overactive Bladder Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Overactive Bladder Drug Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Overactive Bladder Drug in United States 2013-2017
- 2.2 Consumption Market of Overactive Bladder Drug in United States by Regions
 - 2.2.1 Consumption Volume of Overactive Bladder Drug in United States by Regions
 - 2.2.2 Revenue of Overactive Bladder Drug in United States by Regions
- 2.3 Market Analysis of Overactive Bladder Drug in United States by Regions
 - 2.3.1 Market Analysis of Overactive Bladder Drug in New England 2013-2017
 - 2.3.2 Market Analysis of Overactive Bladder Drug in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Overactive Bladder Drug in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Overactive Bladder Drug in The West 2013-2017
 - 2.3.5 Market Analysis of Overactive Bladder Drug in The South 2013-2017
 - 2.3.6 Market Analysis of Overactive Bladder Drug in Southwest 2013-2017
- 2.4 Market Development Forecast of Overactive Bladder Drug in United States 2018-2023
 - 2.4.1 Market Development Forecast of Overactive Bladder Drug in United States 2018-2023

2.4.2 Market Development Forecast of Overactive Bladder Drug by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Overactive Bladder Drug in United States by Types

3.1.2 Revenue of Overactive Bladder Drug in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Overactive Bladder Drug in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Overactive Bladder Drug in United States by Downstream Industry

4.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Overactive Bladder Drug by Downstream Industry in New England

4.2.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Overactive Bladder Drug by Downstream Industry in The Midwest

4.2.4 Demand Volume of Overactive Bladder Drug by Downstream Industry in The West

4.2.5 Demand Volume of Overactive Bladder Drug by Downstream Industry in The South

4.2.6 Demand Volume of Overactive Bladder Drug by Downstream Industry in Southwest

4.3 Market Forecast of Overactive Bladder Drug in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OVERACTIVE BLADDER DRUG

5.1 United States Economy Situation and Trend Overview

5.2 Overactive Bladder Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 OVERACTIVE BLADDER DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Overactive Bladder Drug in United States by Major Players

6.2 Revenue of Overactive Bladder Drug in United States by Major Players

6.3 Basic Information of Overactive Bladder Drug by Major Players

6.3.1 Headquarters Location and Established Time of Overactive Bladder Drug Major Players

6.3.2 Employees and Revenue Level of Overactive Bladder Drug Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 OVERACTIVE BLADDER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma, Inc. (Japan)

7.1.1 Company profile

7.1.2 Representative Overactive Bladder Drug Product

7.1.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Astellas Pharma, Inc. (Japan)

7.2 Pfizer, Inc. (U.S.)

7.2.1 Company profile

7.2.2 Representative Overactive Bladder Drug Product

7.2.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Pfizer, Inc. (U.S.)

7.3 Teva Pharmaceutical Industries Limited (Israel)

7.3.1 Company profile

7.3.2 Representative Overactive Bladder Drug Product

7.3.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited (Israel)

7.4 Allergan, Plc (Ireland)

- 7.4.1 Company profile
- 7.4.2 Representative Overactive Bladder Drug Product
- 7.4.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Allergan, Plc (Ireland)
- 7.5 Medtronic plc (Ireland)
 - 7.5.1 Company profile
 - 7.5.2 Representative Overactive Bladder Drug Product
 - 7.5.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Medtronic plc (Ireland)
- 7.6 Mylan N.V. (U.S.)
 - 7.6.1 Company profile
 - 7.6.2 Representative Overactive Bladder Drug Product
 - 7.6.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Mylan N.V. (U.S.)
- 7.7 Endo International plc (Ireland)
 - 7.7.1 Company profile
 - 7.7.2 Representative Overactive Bladder Drug Product
 - 7.7.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Endo International plc (Ireland)
- 7.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
 - 7.8.1 Company profile
 - 7.8.2 Representative Overactive Bladder Drug Product
 - 7.8.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Hisamitsu Pharmaceutical Co., Inc. (Japan)
- 7.9 Sanofi (France)
 - 7.9.1 Company profile
 - 7.9.2 Representative Overactive Bladder Drug Product
 - 7.9.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Sanofi (France)
- 7.10 Apotex, Inc. (Canada)
 - 7.10.1 Company profile
 - 7.10.2 Representative Overactive Bladder Drug Product
 - 7.10.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Apotex, Inc. (Canada)
- 7.11 Cogentix Medical, Inc. (U.S.)
 - 7.11.1 Company profile
 - 7.11.2 Representative Overactive Bladder Drug Product
 - 7.11.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Cogentix Medical, Inc. (U.S.)

7.12 Aurobindo Pharma Limited (India)

7.12.1 Company profile

7.12.2 Representative Overactive Bladder Drug Product

7.12.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Aurobindo Pharma Limited (India)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OVERACTIVE BLADDER DRUG

8.1 Industry Chain of Overactive Bladder Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OVERACTIVE BLADDER DRUG

9.1 Cost Structure Analysis of Overactive Bladder Drug

9.2 Raw Materials Cost Analysis of Overactive Bladder Drug

9.3 Labor Cost Analysis of Overactive Bladder Drug

9.4 Manufacturing Expenses Analysis of Overactive Bladder Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF OVERACTIVE BLADDER DRUG

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Overactive Bladder Drug-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/O3E6C6A7089MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3E6C6A7089MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970